

Haematologica  
HAEMATOL/2018/187583  
Version 3

TP53 aberrations in chronic lymphocytic leukemia: an overview of the  
clinical implications of improved diagnostics

Elias Campo, Florence Cymbalista, Paolo Ghia, Ulrich Jäger, Sarka  
Pospisilova, Richard Rosenquist, Anna Schuh, and Stephan  
Stilgenbauer

Disclosures: EC reports grants from Spanish Instituto Salud Carlos III, grants from Gilead, during the conduct of the study. FC reports personal fees and non-financial support from Gilead, non-financial support from Roche, personal fees and non-financial support from Abbvie, grants, personal fees and non-financial support from Janssen, grants and personal fees from Sunesis, outside the submitted work. PG reports grants and personal fees from AbbVie, personal fees from Acerta, grants and personal fees from Janssen, grants and personal fees from Gilead, outside the submitted work. UJ reports grants and personal fees from Gilead, grants and personal fees from Janssen, personal fees from AbbVie, grants and personal fees from Roche, grants and personal fees from Celgene, personal fees from BMS, grants and personal fees from Novartis, during the conduct of the study. SP has nothing to disclose. RR reports personal fees from Gilead, personal fees from Roche, personal fees from Jansen, outside the submitted work. AS reports personal fees from GILEAD, personal fees from Janssen, personal fees from ROCHE, personal fees from Abbvie, outside the submitted work. SS reports grants, personal fees and non-financial support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis, Pharmacyclics, Sunesis, during the conduct of the study; grants, personal fees and non-financial support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis, Pharmacyclics, Sunesis, outside the submitted work.

Contributions: All authors contributed equally to this work.